Premium
F131The role of fetal echocardiography during maternal pharmacological treatment
Author(s) -
Krasoń A.,
Kaczmarek P.,
Janiak K.,
RespondekLiberska M.
Publication year - 2000
Publication title -
ultrasound in obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.202
H-Index - 141
eISSN - 1469-0705
pISSN - 0960-7692
DOI - 10.1046/j.1469-0705.2000.00015-1-130.x
Subject(s) - medicine , fetus , gestational age , fetal echocardiography , pregnancy , regurgitation (circulation) , obstetrics , aspirin , apgar score , fetal heart , cardiology , prenatal diagnosis , genetics , biology
Background The aim of this study was retrospective analysis of fetal tricuspid valve regurgitation (TR) during echo in the second half of pregnancy in 100/5079 (1.98%) fetuses with normal heart anatomy (NHA) and without extracardiac malformations (ECM), beetwen 01.01.1994–31.12.1999. Method In this group, 43 (53.75%) cases with TR had treatment: 36 fetuses betamimetics, 4 fetuses indomethacin and 3 fetuses aspirin. In 34 (79.06%) cases trivial TR and in 9 (20.94%) cases holosystolic TR were diagnosed. The mean fetal gestational age was 30.9 ± 4.1 hbd. Twenty neonates (80%) were delivered vaginally and 5 by cesarean section, at mean gestational age of delivery was 37 ± 3.7 hbd. The mean Apgar score was 9 pts. Conclusions 1. Fetal TR with NHA was diagnosed in 53.7% fetuses with maternal treatment. 2. The most common finding of TR with NHA was exposure on betamimetic. 3. Fetal echocardiography was helpful to confirm the safety and fetal well‐being during maternal pharmacological treatment due to premature labour.